Awareness Detection and Communication in Disorders of Consciousness
Launched by UNIVERSITY OF ULSTER · Jan 30, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how to detect awareness in patients with disorders of consciousness, such as those who are in a vegetative state or minimally conscious state. The goal is to find better ways to understand if these patients have any conscious awareness, which is often difficult to assess because they may not be able to respond physically. Researchers are using a technique called electroencephalography (EEG) to measure brain activity while patients try to imagine different movements. By analyzing these patterns, they want to see if patients can communicate "yes" or "no" answers to questions based on their brain activity.
To participate in the trial, individuals should have a diagnosis of a disorder of consciousness or locked-in syndrome and be able to follow instructions. Those who have severe brain conditions or certain medical issues that could interfere with the study will not be eligible. Participants will go through three phases, starting with assessments to see if they can imagine movements, followed by training to help them learn how to use their brain signals to communicate, and finally, they will answer questions to assess their awareness. This research aims to improve how we evaluate and assist patients who are unable to move or speak but may still have some level of consciousness.
Gender
ALL
Eligibility criteria
- • Study 1 - Initial assessment/screening
- Inclusion Criteria:
- • Disorder of consciousness or low awareness state diagnosis ranging from unclear diagnosis in low awareness states, vegetative state and minimally conscious diagnosis. Those with locked in syndrome / completed locked in syndrome resulting from injury or disease e.g., motor neuron disease who do not have health problems that would preclude them from participating may be assessed but considered as a separate cohort to those with low awareness states.
- • acute, post-acute patients where appropriate
- Exclusion Criteria:
- • Participants with brain related diseases or illnesses (e.g., progressive neurological condition or uncontrolled epilepsy) or suffer from pain (these may adversely affect the brain data produced) and are deemed to be unsuitable for the trials by clinical teams.
- • Current consumption of medications that cause excessive fatigue or adversely affect cognitive functioning
- • Where English is not the individual's first language
- • Participant with excessive uncontrollable arm or head movement or teeth grinding as EEG signal quality will be degraded significantly.
- • Study 2 - BCI training
- Inclusion Criteria:
- • - Those identified in study 1 to have a level of awareness based on observed appropriate brain activations and/or those who have known awareness but are target groups for movement independent assistive devices and technologies controlled using a brain-computer interface.
- Exclusion Criteria:
- • - Participants who have shown no active brain responses in study 1 where the difference between baseline
About University Of Ulster
The University of Ulster is a leading academic institution dedicated to advancing knowledge and innovation through research and education. Renowned for its commitment to excellence, the university actively engages in clinical trials aimed at improving healthcare outcomes and addressing pressing health challenges. With a robust infrastructure for research and a multidisciplinary approach, the University of Ulster fosters collaboration among researchers, healthcare professionals, and industry partners. Its focus on evidence-based practices ensures that clinical trials are designed and conducted to the highest ethical and scientific standards, contributing valuable insights to the field of medicine and enhancing patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Warwick, , United Kingdom
Sheffield, , United Kingdom
Barnsley, , United Kingdom
Belfast, , United Kingdom
Oxford, , United Kingdom
Liverpool, , United Kingdom
Portadown, , United Kingdom
Hull, , United Kingdom
Dublin, , Ireland
Antrim, , United Kingdom
Dundonald, , United Kingdom
Edinburgh, , United Kingdom
Londonderry, , United Kingdom
London, , United Kingdom
York, , United Kingdom
Warwick, Warwickshire, United Kingdom
Bristol, , United Kingdom
London, , United Kingdom
Worcester, , United Kingdom
Patients applied
Trial Officials
Damien Coyle, PhD
Principal Investigator
University of Ulster
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials